JP7809117B2 - Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 - Google Patents

Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物

Info

Publication number
JP7809117B2
JP7809117B2 JP2023536095A JP2023536095A JP7809117B2 JP 7809117 B2 JP7809117 B2 JP 7809117B2 JP 2023536095 A JP2023536095 A JP 2023536095A JP 2023536095 A JP2023536095 A JP 2023536095A JP 7809117 B2 JP7809117 B2 JP 7809117B2
Authority
JP
Japan
Prior art keywords
glp
present
composition
compositions
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023536095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553561A5 (https=
JP2023553561A (ja
Inventor
ジェスパー スコドボーグ ビラジェン
リス ジエム
Original Assignee
ジーランド ファーマ エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーランド ファーマ エー／エス filed Critical ジーランド ファーマ エー／エス
Publication of JP2023553561A publication Critical patent/JP2023553561A/ja
Publication of JP2023553561A5 publication Critical patent/JP2023553561A5/ja
Application granted granted Critical
Publication of JP7809117B2 publication Critical patent/JP7809117B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2023536095A 2020-12-16 2021-12-16 Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 Active JP7809117B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20214562 2020-12-16
EP20214562.9 2020-12-16
PCT/EP2021/086147 WO2022129311A1 (en) 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists

Publications (3)

Publication Number Publication Date
JP2023553561A JP2023553561A (ja) 2023-12-22
JP2023553561A5 JP2023553561A5 (https=) 2024-12-23
JP7809117B2 true JP7809117B2 (ja) 2026-01-30

Family

ID=74141274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536095A Active JP7809117B2 (ja) 2020-12-16 2021-12-16 Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物

Country Status (13)

Country Link
US (1) US20240024425A1 (https=)
EP (1) EP4262745B1 (https=)
JP (1) JP7809117B2 (https=)
KR (1) KR20230121823A (https=)
CN (1) CN116710114B9 (https=)
AU (1) AU2021404497A1 (https=)
CA (1) CA3200526A1 (https=)
CL (1) CL2023001747A1 (https=)
ES (1) ES3019509T3 (https=)
IL (1) IL301893A (https=)
MX (1) MX2023006284A (https=)
WO (1) WO2022129311A1 (https=)
ZA (1) ZA202304235B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
IL301892A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
JP2024533153A (ja) * 2021-09-03 2024-09-12 ジーランド ファーマ エー／エス 投薬レジーム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510675A (ja) 2003-11-13 2007-04-26 ノボ　ノルディスク　アクティーゼルスカブ 糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
JP2019525890A (ja) 2016-12-09 2019-09-12 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
MXPA04003569A (es) * 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
CN104902922B (zh) * 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
SG11202111311WA (en) * 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510675A (ja) 2003-11-13 2007-04-26 ノボ　ノルディスク　アクティーゼルスカブ 糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
JP2019525890A (ja) 2016-12-09 2019-09-12 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト

Also Published As

Publication number Publication date
ES3019509T3 (en) 2025-05-20
IL301893A (en) 2023-06-01
CN116710114B (zh) 2025-11-25
CL2023001747A1 (es) 2024-01-19
CA3200526A1 (en) 2022-06-23
MX2023006284A (es) 2023-06-13
US20240024425A1 (en) 2024-01-25
EP4262745C0 (en) 2025-01-29
ZA202304235B (en) 2025-08-27
JP2023553561A (ja) 2023-12-22
KR20230121823A (ko) 2023-08-21
TW202228764A (zh) 2022-08-01
WO2022129311A1 (en) 2022-06-23
EP4262745B1 (en) 2025-01-29
AU2021404497A1 (en) 2023-06-08
CN116710114A (zh) 2023-09-05
EP4262745A1 (en) 2023-10-25
CN116710114B9 (zh) 2026-01-02

Similar Documents

Publication Publication Date Title
JP7580404B2 (ja) Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
JP7809117B2 (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
JP7751641B2 (ja) Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物
AU2021401137B2 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
RU2852511C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855486C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260120

R150 Certificate of patent or registration of utility model

Ref document number: 7809117

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150